CIK 0001549595
- Large accelerated filer
Nurix Therapeutics, Inc.
Sign in to watch- Ticker
- NRIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Nov 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 270838048
- Phone
- +1 415-660-5320
- Business address
- 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
- Former names
- Nurix, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,712,859
- in 10 filings, $1.0M under 10b5-1 plans
Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 50 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-07-30 | Hansen Gwenn Chief Scientific Officer | Option exercise | +2,000 | 31,839 | ||
| 2023-07-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −3,207 | 32,068 | ||
| 2023-07-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −2,000 | 22,000 | ||
| 2023-05-04 | Silva Paul M Director | Grant or award · Director Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2023-05-04 | Saltzman Edward C Director | Grant or award · Director Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2023-05-04 | Reinsdorf Judith A Director | Grant or award · Director Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2023-05-04 | Lacey David L. Director | Grant or award · Director Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2023-05-04 | Kunkel Lori Anne Director | Grant or award · Director Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2023-05-04 | GREGORY JULIA P Director | Grant or award · Director Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2023-05-01 | Wolff Stefani EVP and COO | Sale | −342 | $9.88 | $3K | 6,113 |
| 2023-05-01 | van Houte Hans Chief Financial Officer | Sale | −721 | $9.88 | $7K | 78,930 |
| 2023-05-01 | Ring Christine General Counsel | Sale | −682 | $9.88 | $7K | 10,040 |
| 2023-05-01 | Hansen Gwenn Chief Scientific Officer | Sale | −1,136 | $9.88 | $11K | 26,632 |
| 2023-04-30 | Wolff Stefani EVP and COO | Option exercise | +962 | 6,455 | ||
| 2023-04-30 | Wolff Stefani EVP and COO | Option exercise · Restricted Stock Units | −962 | 10,582 | ||
| 2023-04-30 | van Houte Hans Chief Financial Officer | Option exercise | +2,886 | 79,651 | ||
| 2023-04-30 | van Houte Hans Chief Financial Officer | Option exercise · Restricted Stock Units | −2,886 | 31,747 | ||
| 2023-04-30 | Ring Christine General Counsel | Option exercise | +1,924 | 10,722 | ||
| 2023-04-30 | Ring Christine General Counsel | Option exercise · Restricted Stock Units | −1,924 | 21,165 | ||
| 2023-04-30 | Hansen Gwenn Chief Scientific Officer | Option exercise | +3,206 | 27,768 |
Page 25 of 32 · 632 trades